@article{fcbb96033dda44f0b77c0fa1b44cd6c6,
title = "Stereotactic radiotherapy for prostate bed recurrence after prostatectomy, a multicentric series: BJU International",
abstract = "Objective: To assess the safety and effectiveness of stereotactic salvage radiotherapy (SSRT) in RT-na{\"i}ve patients affected by macroscopic prostate bed recurrence. Patients and methods: Consecutive patients treated for prostate bed macroscopic recurrence in three different Italian institutes were reviewed. Patients were treated with SSRT, with a total dose of 30–40 Gy in five fractions, the mean pre-SSRT PSA level was 2.3 ng/mL. Two different PSA thresholds were defined and biochemical recurrence-free survival (BCRFS) was reported, in order to better express outcome: BCRFS1 (a PSA level increase of >10% compared to the pre-SSRT value) and BCRFS2 (a PSA level increase of >0.2 ng/mL for patients with a PSA nadir of 25% compared to nadir in patients with a PSA nadir of 2 toxicity. Conclusions: SSRT was found to yield significant biochemical control and allowed ADT delay despite adverse features. {\textcopyright} 2019 The Authors BJU International {\textcopyright} 2019 BJU International Published by John Wiley & Sons Ltd",
keywords = "#pcsm, #ProstateCancer, cancer, prostate, radiotherapy, recurrence, stereotactic, antiandrogen, prostate specific antigen, aged, androgen deprivation therapy, Article, cancer radiotherapy, cancer recurrence, human, major clinical study, male, postoperative period, priority journal, prostate cancer, prostatectomy, radiation dose, recurrence free survival, salvage therapy, stereotactic treatment, treatment response, adverse event, clinical trial, multicenter study, prostate tumor, radiosurgery, retrospective study, treatment outcome, tumor recurrence, Aged, Humans, Male, Neoplasm Recurrence, Local, Prostatectomy, Prostatic Neoplasms, Radiosurgery, Retrospective Studies, Salvage Therapy, Treatment Outcome",
author = "G. Francolini and B.A. Jereczek-Fossa and {Di Cataldo}, V. and G. Simontacchi and G. Marvaso and M.A. Zerella and P. Gentile and F. Bianciardi and S. Allegretta and B. Detti and L. Masi and {lo Russo}, M. and L. Livi",
note = "Cited By :2 Export Date: 3 March 2021 CODEN: BJINF Correspondence Address: Francolini, G.; Radiation Oncology Unit, Italy; email: francolinigiulio@gmail.com References: Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2018 (2018) CA Cancer J Clin, 68, pp. 7-30; Tyson, M.D., 2nd, Andrews, P.E., Ferrigni, R.F., Radical prostatectomy trends in the United States: 1998–2011 (2016) Mayo Clin Proc, 91, pp. 10-16; Thompson, I.M., Valicenti, R.K., Albertsen, P., Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO guideline (2013) J Urol, 190, pp. 441-449; Stephenson, A.J., Slawin, K.M., Bianco, F.J., Jr., Perspectives on the natural history of recurrent prostate cancer after radical prostatectomy, based on the response to salvage radiotherapy (2004) BJU Int, 94, pp. 1210-1212; Carrie, C., Hasbini, A., de Laroche, G., Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial (2016) Lancet Oncol, 17, pp. 747-756; Tendulkar, R.D., Agrawal, S., Gao, T., Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy (2016) J Clin Oncol, 34, pp. 3648-3654; Stephenson, A.J., Scardino, P.T., Kattan, M.W., Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy (2007) J Clin Oncol, 25, pp. 2035-2041; Emmett, L., Van Leeuwen, P.J., Nandurkar, R., Treatment outcomes from 68Ga-PSMA PET/CT–informed salvage radiation treatment in men with rising PSA after radical prostatectomy: prognostic value of a negative PSMA PET (2017) J Nucl Med, 58, pp. 1972-1976; King, C.R., The dose-response of salvage radiotherapy following radical prostatectomy: a systematic review and meta-analysis (2016) Radiother Oncol, 121, pp. 199-203; Ohri, N., Dicker, A.P., Trabulsi, E.J., Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modelling (2012) Eur J Cancer, 48, pp. 837-844; Cou{\~n}ago, F., Sancho, G., Catal{\'a}, V., Magnetic resonance imaging for prostate cancer before radical and salvage radiotherapy: what radiation oncologists need to know (2017) World J Clin Oncol, 8, pp. 305-319; Cornford, P., Bellmunt, J., Bolla, M., Guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer (2017) Eur Urol, 71, pp. 630-642; Jereczek-Fossa, B.A., Beltramo, G., Fariselli, L., Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer (2012) Int J Radiat Oncol Biol Phys, 82, pp. 889-897; Scher, H.I., Halabi, S., Tannock, I., Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group (2008) J Clin Oncol, 26, pp. 1148-1159; Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0, , http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-, Accessed April 2019, 14_QuickReference_5x7.pdf; Shipley, W.U., Seiferheld, W., Lukka, H.R., Radiation with or without antiandrogen therapy in recurrent prostate cancer (2017) N Engl J Med, 376, pp. 417-428; Bartkowiak, D., Thamm, R., Bottke, D., Prostate-specific antigen after salvage radiotherapy for postprostatectomy biochemical recurrence predicts long-term outcome including overall survival (2018) Acta Oncol, 57, pp. 362-367; Stish, B.J., Pisansky, T.M., Harmsen, W.S., Improved metastasis-free and survival outcomes with early salvage radiotherapy in men with detectable prostate-specific antigen after prostatectomy for prostate cancer (2016) J Clin Oncol, 34, pp. 3864-3871; Hershman, D.L., Unger, J.M., Wright, J.D., Adverse health events following intermittent and continuous androgen deprivation in patients with metastatic prostate cancer (2016) JAMA Oncol, 2, pp. 453-461; Brenner, D.J., Hall, E.J., Are we now able to define guidelines for moderate hypofractionation in prostate cancer radiation therapy? (2018) Int J Radiat Oncol Biol Phys, 100, pp. 871-873; Perera, M., Papa, N., Christidis, D., Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis (2016) Eur Urol, 70, pp. 926-937; von Eyben, F.E., Picchio, M., von Eyben, R., (68)Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/computed tomography for prostate cancer: a systematic review and meta- analysis (2018) Eur Urol Focus, 4, pp. 686-693; Dirix, P., van Walle, L., Deckers, F., Proposal for magnetic resonance imaging-guided salvage radiotherapy for prostate cancer (2017) Acta Oncol, 56, pp. 27-32; Hernandez, D., Salas, D., Gim{\'e}nez, D., Pelvic MRI findings in relapsed prostate cancer after radical prostatectomy (2015) Radiat Oncol, 10, p. 262; Detti, B., Bonomo, P., Masi, L., CyberKnife stereotactic radiotherapy for isolated recurrence in the prostatic bed (2016) World J Urol, 34, pp. 311-317",
year = "2020",
doi = "10.1111/bju.14924",
language = "English",
volume = "125",
pages = "417--425",
journal = "BJU Int.",
issn = "1464-4096",
publisher = "Blackwell Publishing Ltd",
number = "3",
}